BACKGROUND: Measurement of human immunodeficiency virus(HIV) incidence among female sex workers in Rwanda is a key part of preparing for HIV prevention trials. METHODS: HIV-negative, nonpregnant female sex workers (N =397) were tested for HIV-1, sexually transmitted infections, and pregnancy quarterly for 12 months, and again at a 1-time year 2 visit. Additional women (N=156) were tested for HIV at baseline and 6 to 12 months thereafter in a parallel study. RESULTS: A total of 19 participants seroconverted during follow-up,with 13 in the first 12 months. The 12-month HIV incidence rate (IR)was 3.5 (95% confidence interval: 1.6, 5.4) per 100 person-years (PY).There was a nonsignificant downward trend from 4.6/100 PY (1.6, 7.7)in the first 6 months to 2.2 (0.1, 4.4) in the second 6 months (IR ratio:2.1 [95% confidence interval: 0.7, 7.8]). The year 2 IR was 2.1 (0.4,3.7), and the HIV IR in the parallel study (in the absence of frequent study visits) was 3.3/100 PY (0, 7.0). HIV testing history, lifetime pregnancies, recent initiation of sex work, gonorrhea, syphilis, and change in reproductive intentions were associated with incident HIV infection. Incidence of pregnancy, herpes simplex virus-type 2,trichomoniasis, gonorrhea, chlamydia, and syphilis per 100 PY were as follows: 26.3 (21.9, 30.7), 8.7 (4.0, 13.4), 16.9 (12.7, 21.1), 12.1 (8.2,15.9), 8.1 (5.1, 11.2), and 6.2 (3.7, 8.7). CONCLUSIONS: The HIV/sexually transmitted infections burden int his group was high. HIV IR was highest in the first 6 months of the cohort, and in the parallel study in which there were no risk-reduction procedures. HIV prevention and family planning interventions are needed.
BACKGROUND: Measurement of human immunodeficiency virus(HIV) incidence among female sex workers in Rwanda is a key part of preparing for HIV prevention trials. METHODS: HIV-negative, nonpregnant female sex workers (N =397) were tested for HIV-1, sexually transmitted infections, and pregnancy quarterly for 12 months, and again at a 1-time year 2 visit. Additional women (N=156) were tested for HIV at baseline and 6 to 12 months thereafter in a parallel study. RESULTS: A total of 19 participants seroconverted during follow-up,with 13 in the first 12 months. The 12-month HIV incidence rate (IR)was 3.5 (95% confidence interval: 1.6, 5.4) per 100 person-years (PY).There was a nonsignificant downward trend from 4.6/100 PY (1.6, 7.7)in the first 6 months to 2.2 (0.1, 4.4) in the second 6 months (IR ratio:2.1 [95% confidence interval: 0.7, 7.8]). The year 2 IR was 2.1 (0.4,3.7), and the HIV IR in the parallel study (in the absence of frequent study visits) was 3.3/100 PY (0, 7.0). HIV testing history, lifetime pregnancies, recent initiation of sex work, gonorrhea, syphilis, and change in reproductive intentions were associated with incident HIV infection. Incidence of pregnancy, herpes simplex virus-type 2,trichomoniasis, gonorrhea, chlamydia, and syphilis per 100 PY were as follows: 26.3 (21.9, 30.7), 8.7 (4.0, 13.4), 16.9 (12.7, 21.1), 12.1 (8.2,15.9), 8.1 (5.1, 11.2), and 6.2 (3.7, 8.7). CONCLUSIONS: The HIV/sexually transmitted infections burden int his group was high. HIV IR was highest in the first 6 months of the cohort, and in the parallel study in which there were no risk-reduction procedures. HIV prevention and family planning interventions are needed.
Authors: Mwumvaneza Mutagoma; Malamba S Samuel; Catherine Kayitesi; Antoine R Gasasira; Bassirou Chitou; Kimberly Boer; Bethany Hedt-Gauthier; Neil Gupta; Joseph Ntaganira; Sabin Nsanzimana Journal: Int J STD AIDS Date: 2017-01-12 Impact factor: 1.359
Authors: Ângelo do Rosário Augusto; Peter W Young; Roberta Z Horth; Celso Inguane; Isabel Sathane; Katia Ngale; Marcos Benedetti; Beverley Cummings; Carlos Francisco Sande Botão; Cynthia Amino Semá Baltazar; Heidi Frank; Jennifer Fagan; Henry Fisher Raymond; Willi McFarland Journal: AIDS Behav Date: 2016-04
Authors: Hanneke Borgdorff; Evgeni Tsivtsivadze; Rita Verhelst; Massimo Marzorati; Suzanne Jurriaans; Gilles F Ndayisaba; Frank H Schuren; Janneke H H M van de Wijgert Journal: ISME J Date: 2014-03-06 Impact factor: 10.302
Authors: H Borgdorff; R Gautam; S D Armstrong; D Xia; G F Ndayisaba; N H van Teijlingen; T B H Geijtenbeek; J M Wastling; J H H M van de Wijgert Journal: Mucosal Immunol Date: 2015-09-09 Impact factor: 7.313
Authors: Mirte Scherpenisse; Rutger M Schepp; Madelief Mollers; Chris J L M Meijer; Guy A M Berbers; Fiona R M van der Klis Journal: PLoS One Date: 2013-09-18 Impact factor: 3.240
Authors: Nienke J Veldhuijzen; Sarah L Braunstein; Joseph Vyankandondera; Chantal Ingabire; Justin Ntirushwa; Evelyne Kestelyn; Coosje Tuijn; Ferdinand W Wit; Aline Umutoni; Mireille Uwineza; Tania Crucitti; Janneke H H M van de Wijgert Journal: BMC Infect Dis Date: 2011-12-02 Impact factor: 3.090
Authors: Lauren A Graybill; Margaret Kasaro; Kellie Freeborn; Jennifer S Walker; Charles Poole; Kimberly A Powers; Katie R Mollan; Nora E Rosenberg; Sten H Vermund; Wilbroad Mutale; Benjamin H Chi Journal: AIDS Date: 2020-04-01 Impact factor: 4.632
Authors: Marissa Becker; Satyanarayana Ramanaik; Shiva Halli; James F Blanchard; T Raghavendra; Parinita Bhattacharjee; Stephen Moses; Lisa Avery; Sharmistha Mishra Journal: AIDS Res Treat Date: 2012-12-30